THE EFFECT OF HYPERCHOLESTEROLEMIA ON CORTICAL BONE THICKNESS OF WISTAR RATS (Rattus norvegicus)

Auliya Dzaqiyatus Sofka, Pudji Lestari, Gadis Meinar Sari
1Medical Education Study Program, 2Department of Public Health, 3Department of Physiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

ABSTRACT

There have been several studies reporting the effect of hypercholesterolemia on cortical thickness, but it remains a controversy. Some studies suggest that hypercholesterolemia can decrease osteoblast activity and increase osteoclast activity. Meanwhile other studies suggest that hypercholesterolemia is a protective factor of osteoporosis. Therefore, it is necessary to conduct a study to determine the effect of hypercholesterolemia on cortical bone thickness. Method: This study used 8 rats (Rattus norvegicus) that were divided into 2 groups, including control group (K0) that was given standard diet and experimental group (K1) that was given high fat diet for 28 days and all were executed to obtain the femur bone. The cortical bone thickness was measured by using Optilab Viewer and Optilab Image Raster software. Result: The data analysis was conducted using independent t-test. A p value of <0.05 is considered significant. The results showed that hypercholesterolemia had significant effect on cortical bone thickness. The average cortical bone thickness in the control group was 146.92 µm whereas in the experimental group was 124.53 µm, the mean difference between the two groups was 22.39 µm. There was a 6% decrease of cortical bone thickness. In conclusion, hypercholesterolemia can decrease cortical bone thickness of wistar rats (Rattus norvegicus).

Keywords: Hypercholesterolemia, cortical bone thickness

INTRODUCTION

Hypercholesterolemia is defined as high plasma cholesterol level exceeding the normal range for healthy population. Total cholesterol level in adults is considered high if it reaches 240 mg/dL or above. Meanwhile, as for children and adolescents, the normal cut-off value for total cholesterol level is 200 mg/dL (Rantung et al 2014). Hypercholesterolemia is also characterized by an increase in total cholesterol level, low density lipoprotein (LDL) cholesterol, and triglycerides as well as a decrease in High Density Lipoprotein (HDL) cholesterol (Murray et al 2014). Elevation in blood cholesterol levels is associated with decrease bone thickness and increase risk of bone fractures (Cao 2011).
An increasing percentage of fat mass in the body occurs on people who suffer from hypercholesterolemia. The percentage of body fat is positively related with osteopenia and non-spine fractures. Proinflammatory cytokines are able to stimulate osteoclast activity through activation of RANKL/RANK/OPG pathway (Pfeilschifter et al. 2002). Besides, according to other studies, high cholesterol level can induce cathepsin K which directly increases RANKL production that subsequently binds to RANK receptor on the surface osteoclasts. Osteoclast activation induces osteoclastogenesis process which increases osteoclast production (Mandal 2015).

Another study explains that leptin clearly increases cell proliferation through the Saos2 cell pathway mediated by PI(3)K. Leptin also activates MAPK (Mitogen Activated Protein Kinase) which also mediates the Saos2 cell pathway leading to increase cell proliferation. Leptin has a significant peripheral effect on bone mass. Leptin and its receptors are expressed in osteoblast cells and persistent leptin exposure could increase collagen synthesis, mineralization and osteoblast cell differentiation (Burguerra et al 2006).

From the background described above, the relationship between hypercholesterolemia and bone thickness remains unclear. Hence, the author intended to investigate the effects of hypercholesterolemia on bone metabolism, especially its impact on the reduction of bone density resulted from increased bone resorption by osteoclasts. In general, bone density measurement was conducted using densitometry apparatus and biochemical test; however, in this study the author was interested in measuring bone density from the cortical part of the bone. Measuring the width of the cortex which has high sensitivity and specificity in detecting osteoporosis can also be applied for measuring bone thickness (Alvarez et al 1997).

MATeRIALS AND METHoDS

In hypercholesterolemia, there is an increase in osteoclast activity, suppression of osteoblast activity, and reduction in bone remodelling among experimental rats with hyperlipidaemia (Krieger 1998). One study Luegmayr et al (2004) found that elevating plasma cholesterol levels induces imbalance in bone remodelling process and reduction of bone mass by increasing the activity and differentiation of osteoclast. Numerous previous studies concluded that hypercholesterolemia affects bone structure through various mechanisms. One of the consequences of hypercholesterolemia is reduction in bone thickness. A study Majima et al (2008) proved that patients with hypercholesterolemia have increase bone-specific alkaline phosphatase (BAP) and N-terminal telopeptide of type 1 collagen (Ntx) which are two of many markers for bone resorption. In addition, an animal study have shown that hypercholesterolemia increases osteoclast activity and reduces bone thickness in mice model (Majima et al 2008, Krieger 1998).

This study used 8 wistar rats (Rattus norvegicus) which were divided into 2 groups, including control group (K0) that was given standard diet and experimental group (K1) that was given high fat diet. According to Basso and Heersche (2006) execution and bone removal was done after 28 days of high cholesterol diet for experimental group and anytime for the control group. A study conducted by Gani et al (2013) showed that the cortical bone is removed from the muscle and other soft tissues around the bone, fixated for 72 hours in 4% of paraformaldehyde and decalcified for approximately 1 week using Na-Citrate. After decalcification, the specimen is embedded in paraffin and several transverse slices are made for each bone with 5µm thickness. Staining of the preparation was performed using hematoxylin-eosin (HE) stain (Gani et al 2013).

Each transverse slice was evaluated microscopically. The length of the periosteal and endosteal surfaces of at least 10 bone axes were measured using Optilab Viewer and Optilab Image Raster software in the histology laboratory of Faculty of Medicine Airlangga University. The mean length of periosteal and endosteal surfaces is presented to represent the cortical bone thickness.

Data were tabulated and descriptive analysis was conducted. After normality (Kolmogorov-smirnov test) and homogeneity (Levene's test) tests, parametric or non-parametric test was performed. Independent t-test was used for a set of normally distributed and homogenous data.

RESULTS

Histopathology examination was performed to determine the cortical bone thickness in both groups by measuring the 10 axis points (Fig. 1) and (Fig. 2).

The mean cortical bone thickness for control group and experimental group are 146.92 µm and 124.53 µm, respectively (Table 1). The mean difference between control group (K0) and experimental group (K1) is 22.39 µm. We found 6% reduction of the cortical bone thickness in experimental group compared to control group. The results of Levene's test and Kolmogorov-smirnov test showed that our data were homogeneous and had normal distribution.
Fig. 1. Histological image of samples obtained from the control group (K0) (40x magnitude).

Fig. 2. Histological image of samples obtained from the experimental group (K1) (40x magnitude).

Table 1. Measurement of cortical bone thickness in control group (K0) and experimental group (K1)

<table>
<thead>
<tr>
<th>Sample</th>
<th>Cortical Bone Thickness (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control Group (K0)</td>
</tr>
<tr>
<td>1</td>
<td>176.42</td>
</tr>
<tr>
<td>2</td>
<td>140.02</td>
</tr>
<tr>
<td>3</td>
<td>165.41</td>
</tr>
<tr>
<td>4</td>
<td>159.38</td>
</tr>
<tr>
<td>Mean</td>
<td>146.92</td>
</tr>
</tbody>
</table>

Table 2. Analysis of cortical bone thickness in control group (K0) and hypercholesterolemia group (K1)

<table>
<thead>
<tr>
<th>Cortical bone thickness</th>
<th>Control Group (n = 4)</th>
<th>Experimental Group (n = 4)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>146.92</td>
<td>124.53</td>
<td>&lt;0.005</td>
</tr>
</tbody>
</table>

Therefore, independent t-test was employed to test for statistical significance. The cortical bone thickness in experimental group was significantly lower compared to the control group (p<0.005). The result was presented in Table 2.

DISCUSSION

Hypercholesterolemia reduces bone mass which causes osteoporosis. This works as warning that hypercholesterolemia can potentially harm bone health (Majima et al. 2008). There is a theory showing that increased adipocyte cells in people who suffer from hypercholesterolemia can also increase leptin production. As a result, reduction of bone mass occurs due to brain stimulation that releases hypothalamic osteoblast inhibitory factor (HOBIF). Furthermore, the activation of ObRb (long leptin isoform receptor) in the hypothalamus stimulates HOBIF in which once secreted, it will decrease osteoblast activity to form the bone matrix. Another indirect mechanism for regulation of this substance is through activation Y2 receptors by...
neuropeptide Y (NPY) that stimulates HOBIF secretion (Siswo 2013).

Another study explains that leptin clearly increases cell proliferation through the Saos2 cell pathway that is mediated by PI (3) K. Leptin also activates MAPK (Mitogen Activated Protein Kinase) which also mediates the Saos2 cell pathway leading to increase cell proliferation. Leptin has significant peripheral effect on bone mass. Leptin and its receptor are expressed in the surface of osteoblast cells and long-term leptin exposure could increase collagen synthesis, mineralization and differentiation of osteoblast. This shows that mechanism on how leptin exerts its effects on bone metabolism remains to be elucidated. According to Burguerra et al (2006), several different pathways involved in these mechanisms lead to different results depending on the leptin dose.

On the other hand, hypercholesterolemia can induce cathepsin K of osteoclasts that are positively correlated with RANKL expression leading to increase osteoclastogenesis (Mandal 2015). Cathepsin K secreted by osteoclasts can resorb the bone and destroy the bone matrix which consists mostly of type 1 collagen (Now & Nandeesh 2012). RANKL stimulates osteoclastogenesis by binding RANK receptors on the surface of osteoclast precursors and mature osteoclast cells and directing the osteoclast precursors (macrophages/monocytes) to osteoclastogenesis (Chapter & Sela 2012). Furthermore, according to a study conducted by Majima et al (2008), hypercholesterolemic patients have increased bone-specific alkaline phosphatase (BAP) and N-terminal telopeptide of type I collagen (Ntx), which are two of many bone resorption markers. Moreover, the animal studies showed that hypercholesterolemia increases osteoclastic potential and reduces bone mass density in rats (Tintut et al 2003, Majima 2008).

According to Mandal (2015), high cholesterol diet given to experimental rats affects osteoblasts and osteoclast activities. As for osteoblast, reduction in BMP-2, ALP, Runx2, Collagen A1 results in decrease osteoblast cell proliferation whereas in osteoclasts, there is an increase in Tartate Resistant Acid Phospate (Trap) production, a bone resorption marker. This notion is also supported by a study stated that osteoblast activity is increased by statins (anti- cholesterol drugs). Furthermore, statins can inhibit osteoclast cell activity. Therefore, cholesterol reduction may inhibit osteoblasts apoptosis and increase osteoclasts apoptosis. The mechanism described above may be one of many mechanisms that cause reduction in bone density caused by hypercholesterolemia (Mandal 2015).

**CONCLUSION**

According to the results presented in this study on the effect of hypercholesterolemia on cortical bone thickness of Wistar rats (*Rattus norvegicus*), it can be concluded that mean cortical bone thickness in hypercholesterolemic Wistar rats was 124.53 µm. The study also found that cortical bone thickness of hypercholesterolemic wistar rats (*Rattus norvegicus*) is lower than those who have normal cholesterol level.

**REFERENCES**


Siswo L (2013). Obesity and bone loss, how to do? eprints.unsri